RNA干扰人永生化食管上皮恶变细胞中核干细胞因子对PI3K/AKT表达的影响  

RNA interfering effect of nucleostemin on expression of PI3K/AKT in Shantou human embryonic esophageal carcinoma epithelial cells

作　　者：胡梦竹 王娟[2] 王盼盼[1] 张洪磊[1] 张霞[1] 张巧[3] 高社干[4] 张功员[1] 

机构地区：[1]郑州大学公共卫生学院流行病学教研室,郑州450001 [2]河北省人民医院病案统计室,石家庄050000 [3]郑州大学公共卫生学院卫生毒理学教研室,郑州450001 [4]河南科技大学第一附属医院肿瘤内科,洛阳471000

出　　处：《郑州大学学报（医学版）》2016年第6期700-703,共4页Journal of Zhengzhou University(Medical Sciences)

基　　金：河南省基础研究资助项目132300410129;河南省教育厅科技攻关资助项目13A330632

摘　　要：目的:研究抑制人永生化食管上皮恶变细胞(SHEEC)中核干细胞因子(NS)对PI3K/AKT信号转导通路中相关分子表达的影响。方法:将干扰试剂(NS-RNAi)转染至SHEEC中以抑制NS的表达,以SHEEC组、阴性对照组(NC组)和MOCK组为对照,采用RT-PCR和Western blot方法检测干扰后PI3K/AKT通路中相关因子mRNA和蛋白表达水平的变化。结果:NS-RNAi成功转染至SHEEC中。抑制SHEEC中NS的表达后PI3K和AKT mRNA的相对表达量为(0.460±0.207)和(0.492±0.233),与SHEEC组、NC组和MOCK组比较,差异有统计学意义(P均<0.05);干扰NS表达后PI3K和AKT蛋白的相对表达量为(0.353±0.361)和(0.312±0.068),与SHEEC组、NC组和MOCK组比较,差异有统计学意义(P均<0.05)。结论:抑制SHEEC中NS表达后PI3K/AKT信号通路中相关因子的表达均明显下降,PI3K/AKT信号通路可能是NS发挥作用的一种非依赖P53作用的信号途径。Aim： To explore the effect of inhibiting nucleostemin（ NS） on PI3K/AKT signal pathway in SHEEC.Methods： RNA interfering agents（ NS-RNAi） was transfected into SHEEC to inhibit the expression of NS gene,with the SHEEC group,negative control（ NC） group,and MOCK group as control,and the expressions of PI3K/AKT pathway related factors were detected by using RT-PCR and Western blot methods. Results： SHEEC was transfected by NS-RNAi and the transfection rate was high. The expression levels of PI3K and AKT mRNA[（ 0. 460 ± 0. 207） and（ 0. 492 ± 0. 233） ]were obviously down-regulated by inhibiting NS gene in comparison with SHEEC,NC and MOCK groups（ P〈0. 05）. The expression levels of PI3K and AKT proteins were（ 0. 353 ± 0. 361） and（ 0. 312 ± 0. 068）,and showed significant difference in comparison with SHEEC,NC and MOCK groups（ P〈0. 05）. Conclusion： The expressions of PI3K/AKT signal pathway related factors decrease with NS down-regulation in SHEEC,and the PI3K/AKT signal pathway may be a kind of NS P53-independent pathway.

关 键 词：永生化食管上皮恶变细胞 核干细胞因子 RNA干扰 PI3K/AKT信号转导通路 

分 类 号：R735.1[医药卫生—肿瘤]